Science Advancement and Outreach

Science Advancement and Outreach

@SAOscience

Jan 9

🖥️ In silico technology is revolutionizing rare disease research! 🦓 Computational models, machine learning, and digital twins can: ✅ Integrate complex data ✅ Simulate biology ✅ Predict actionable outcomes Read more in this @npjDigitalMed review by Pistollato, @Marshall_LJ, @janhealy2, @flora_musuamba et al., of @humaneworldeat, the @COMBINE_Group at @uni_ct, and @narilis_namur: nature.com/articles/s41746-0… This work was supported by the @HorizonEU @ErametProject.

Figure 1 from the linked paper showing a ‘Schematic representation of in silico methods across the rare disease therapeutic pipeline.’ The caption reads: “Methods span from diagnosis (e.g., variant analysis) to drug discovery (e.g., virtual screening), preclinical development (e.g., disease modeling), and clinical trials (e.g., virtual patients, pharmacokinetics/ pharmacodynamics (PK/PD) modeling). Abbreviations: PBPK physiologically based pharmacokinetics, popPK population pharmacokinetics, HTS, high-throughput screening, QSAR quantitative structure–activity relationship.”

ALT Figure 1 from the linked paper showing a ‘Schematic representation of in silico methods across the rare disease therapeutic pipeline.’ The caption reads: “Methods span from diagnosis (e.g., variant analysis) to drug discovery (e.g., virtual screening), preclinical development (e.g., disease modeling), and clinical trials (e.g., virtual patients, pharmacokinetics/ pharmacodynamics (PK/PD) modeling). Abbreviations: PBPK physiologically based pharmacokinetics, popPK population pharmacokinetics, HTS, high-throughput screening, QSAR quantitative structure–activity relationship.”

128